Search research articles
Contact Us
Filters
Showing results (501-510 of 516) with videos related to
Page
of 52
Sort By:
Blood
|
February 21, 2008
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Anja Möricke, Alfred Reiter, Martin Zimmermann, et al.
The British Journal of Nutrition
|
February 16, 2016
Higher PUFA and n-3 PUFA, conjugated linoleic acid, α-tocopherol and iron, but lower iodine and selenium concentrations in organic milk: a systematic literature review and meta- and redundancy analyses
Dominika Średnicka-Tober, Marcin Barański, Chris J Seal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)
Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Blood
|
February 16, 2010
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter, Claus R Bartram, Maria Grazia Valsecchi, et al.
Blood
|
February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000
Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Archives of Disease in Childhood
|
January 1, 1996
The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas
M Weinreb, P J Day, F Niggli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2023
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study
Valentino Conter, Maria Grazia Valsecchi, Gunnar Cario, et al.
Circulation Research
|
June 11, 2021
Impaired Binding to Junctophilin-2 and Nanostructural Alteration in CPVT Mutation
Liheng Yin, Alexandra Zahradnikova, Riccardo Rizzetto, et al.
Cancers
|
April 30, 2021
Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
Birgit Burkhardt, Mary Taj, Nathalie Garnier, et al.
Cancer Cell
|
February 12, 2015
Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors
Jenny Wegert, Naveed Ishaque, Romina Vardapour, et al.
Page
of 52
Search research articles
Search
Showing results (501-510 of 516) with videos related to
Sort By:
Page
of 52
Blood
|
February 21, 2008
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Anja Möricke, Alfred Reiter, Martin Zimmermann, et al.
The British Journal of Nutrition
|
February 16, 2016
Higher PUFA and n-3 PUFA, conjugated linoleic acid, α-tocopherol and iron, but lower iodine and selenium concentrations in organic milk: a systematic literature review and meta- and redundancy analyses
Dominika Średnicka-Tober, Marcin Barański, Chris J Seal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)
Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Blood
|
February 16, 2010
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter, Claus R Bartram, Maria Grazia Valsecchi, et al.
Blood
|
February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000
Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Archives of Disease in Childhood
|
January 1, 1996
The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas
M Weinreb, P J Day, F Niggli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2023
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study
Valentino Conter, Maria Grazia Valsecchi, Gunnar Cario, et al.
Circulation Research
|
June 11, 2021
Impaired Binding to Junctophilin-2 and Nanostructural Alteration in CPVT Mutation
Liheng Yin, Alexandra Zahradnikova, Riccardo Rizzetto, et al.
Cancers
|
April 30, 2021
Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
Birgit Burkhardt, Mary Taj, Nathalie Garnier, et al.
Cancer Cell
|
February 12, 2015
Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors
Jenny Wegert, Naveed Ishaque, Romina Vardapour, et al.
Page
of 52